teclistamab | International Myeloma Foundation

researcher with pipette

Week in Review

April 30

March and April 2026: What's New in Myeloma? 

African-American female researcher in laboratory

Week in Review

March 26

February and March 2026: What's New in Myeloma? 

attendees of an ASH 2025 presentation

Week in Review

February 12

Dr. Joseph Mikhael's Top 10 Myeloma Abstracts from ASH 2025

researcher doing lab work blood samples

Week in Review

January 29

December 2025 and January 2026: What's New in Myeloma?

MajesTEC-3

January 12

MajesTEC-3: Teclistamab-Daratumumab Establishes New Standard of Care in Early Relapsed Myeloma

IMS 2025

Week in Review

December 4

Top Takeaways from the 2025 International Myeloma Society Annual Meeting

FDA building

Week in Review

November 20

October and November 2025: What's New in Myeloma? 

How frequently should TECVAYLI (teclistamab) be given to myeloma patients?

July 5

How frequently should TECVAYLI (teclistamab) be given to myeloma patients?

$MajesTEC-1: Longer Follow-up Teclistamab + Tocilizumab Prophylaxis for CRS in Relapsed/Refractory Myeloma$

June 21

MajesTEC-1: Longer Follow-up Teclistamab + Tocilizumab Prophylaxis for CRS in Relapsed/Refractory Myeloma

Bispecific Antibodies: Using Different Targets to Destroy Multiple Myeloma

Emerging Therapies

September 14

Using Different Targets to Destroy Multiple Myeloma

ASCO23- Dr. Saad Usmani on MajesTEC-1

June 26

Durability of Responses with Biweekly Dosing of Teclistamab in Patients With Relapsed/Refractory Myeloma

ASCO 2023: Dr Yael Cohen presents results of the RedirecTT-1 clinical trial

June 19

RedirecTT-1 Study: Dual Targeting of BCMA and GPRC5D in RRMM Patients with Teclistamab and Talquetamab

Subscribe to teclistamab

Give Where Most Needed